Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (9.9), the stock would be worth ¥11.23 (35% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 15.2 | ¥17.16 |
0%
|
| 3-Year Average | 9.9 | ¥11.23 |
-35%
|
| 5-Year Average | 9.4 | ¥10.57 |
-38%
|
| Industry Average | 29.4 | ¥33.24 |
+94%
|
| Country Average | 28.9 | ¥32.67 |
+90%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
¥113.2B
|
/ |
Oct 2025
¥7.5B
|
= |
|
|
¥113.2B
|
/ |
Dec 2025
¥10.2B
|
= |
|
|
¥113.2B
|
/ |
Dec 2026
¥10.1B
|
= |
|
|
¥113.2B
|
/ |
Dec 2027
¥11.3B
|
= |
|
|
¥113.2B
|
/ |
Dec 2028
¥11B
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
63.6B CNY | 15.2 | 11.3 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
116.5B USD | 21.3 | 26.8 | |
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
70.4B USD | 19.2 | 43.3 | |
| US |
|
Cencora Inc
NYSE:COR
|
70.2B USD | 19.2 | 43.2 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
53.2B USD | 20 | 32 | |
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
34.8B AUD | 49.2 | 65.2 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
9.1B USD | 15.8 | 23.6 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
63.1B CNY | 13.2 | 17.1 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
67B HKD | 2.1 | 8.8 | |
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | 61.9 | 89.6 | |
| AU |
E
|
EBOS Group Ltd
OTC:EBOSY
|
7.1B USD | 27.4 | 47.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 16.6 |
| Median | 28.9 |
| 70th Percentile | 52.9 |
| Max | 49 021 |
Other Multiples
Shanghai Pharmaceuticals Holding Co Ltd
Glance View
Shanghai Pharmaceuticals Holding Co Ltd, a giant in China's pharmaceutical industry, operates with a dual-engine strategy that seamlessly combines manufacturing and distribution. Established in the bustling metropolis of Shanghai, the company has swiftly become a cornerstone of China's healthcare landscape. Its manufacturing arm is a powerhouse of innovation and production, turning out a vast array of pharmaceutical products that encompass both traditional Chinese medicine and modern pharmaceuticals. These products range from patented medicines to essential generics, entering hospitals, clinics, and retail pharmacies nationwide, all the while feeding a robust supply chain that caters to the country's vast and diverse market needs. On the flip side, Shanghai Pharmaceuticals' extensive distribution network is the lifeline that ensures these vital medicines reach their destinations safely and efficiently. In an era where logistics and supply chain management are pivotal, the company excels through an advanced distribution system that connects manufacturers with end-users across China. This network is bolstered by strategic partnerships and a commitment to technological advancement, allowing the company to maintain agility and reliability in an ever-evolving market. Revenue streams flow not just from product sales but are heavily supplemented through strategic partnerships and services that enhance accessibility and affordability for healthcare providers and patients alike. As one of the top pharmaceutical firms in China, Shanghai Pharmaceuticals is adept at maneuvering the intricacies of healthcare demands, regulatory landscapes, and competitive dynamics, carving its niche as a leader in both innovation and distribution efficiency.